Global RNAi for Therapeutic Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Report ID: GIR2112290352 | Category: Medical Care | Pages: 101 | Format: PDF | Published Date: November 17,2022

Request Sample Enquiry before buying Ask For Discount

Single User-$3480.00 Multi User-$5220.00

Report Description
View Table of Contents

Report Summary

The RNAi for Therapeutic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global RNAi for Therapeutic market size is estimated to be worth US$ 181.1 million in 2021 and is forecast to a readjusted size of USD 2031.2 million by 2028 with a CAGR of 41.2% during review period. Cancer accounting for  % of the RNAi for Therapeutic global market in 2021, is projected to value USD   million by 2028, growing at a  % CAGR in next six years. While siRNA segment is altered to a  % CAGR between 2022 and 2028.
Global key companies of RNAi for Therapeutic include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, and Mirna Therapeutics, etc. In terms of revenue, the global top four players hold a share over  % in 2021.
Market segmentation
RNAi for Therapeutic market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
    siRNA
    miRNA
    shRNA
Market segment by Application, can be divided into
    Cancer
    Cardiovascular
    HBV
    Others
Market segment by players, this report covers
    Alnylam Pharmaceuticals
    Arbutus Biopharma (Tekmira)
    Arrowhead
    Dicerna Pharmaceuticals
    Mirna Therapeutics
    Quark Pharmaceuticals
    RXi Pharmaceuticals
    Silence Therapeutics
    Benitec Biopharma
    miRagen Therapeutics
    Sylentis
    Gradalis
    Sirnaomics
    Silenseed
Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe RNAi for Therapeutic product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of RNAi for Therapeutic, with revenue, gross margin and global market share of RNAi for Therapeutic from 2019 to 2022.
Chapter 3, the RNAi for Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and RNAi for Therapeutic market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe RNAi for Therapeutic research findings and conclusion, appendix and data source.

1 Market Overview
    1.1 Product Overview and Scope of RNAi for Therapeutic
    1.2 Classification of RNAi for Therapeutic by Type
        1.2.1 Overview: Global RNAi for Therapeutic Market Size by Type: 2017 Versus 2021 Versus 2028
        1.2.2 Global RNAi for Therapeutic Revenue Market Share by Type in 2021
        1.2.3 siRNA
        1.2.4 miRNA
        1.2.5 shRNA
    1.3 Global RNAi for Therapeutic Market by Application
        1.3.1 Overview: Global RNAi for Therapeutic Market Size by Application: 2017 Versus 2021 Versus 2028
        1.3.2 Cancer
        1.3.3 Cardiovascular
        1.3.4 HBV
        1.3.5 Others
    1.4 Global RNAi for Therapeutic Market Size & Forecast
    1.5 Global RNAi for Therapeutic Market Size and Forecast by Region
        1.5.1 Global RNAi for Therapeutic Market Size by Region: 2017 VS 2021 VS 2028
        1.5.2 Global RNAi for Therapeutic Market Size by Region, (2017-2022)
        1.5.3 North America RNAi for Therapeutic Market Size and Prospect (2017-2028)
        1.5.4 Europe RNAi for Therapeutic Market Size and Prospect (2017-2028)
        1.5.5 Asia-Pacific RNAi for Therapeutic Market Size and Prospect (2017-2028)
        1.5.6 South America RNAi for Therapeutic Market Size and Prospect (2017-2028)
        1.5.7 Middle East and Africa RNAi for Therapeutic Market Size and Prospect (2017-2028)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 RNAi for Therapeutic Market Drivers
        1.6.2 RNAi for Therapeutic Market Restraints
        1.6.3 RNAi for Therapeutic Trends Analysis
2 Company Profiles
    2.1 Alnylam Pharmaceuticals
        2.1.1 Alnylam Pharmaceuticals Details
        2.1.2 Alnylam Pharmaceuticals Major Business
        2.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions
        2.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.1.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
    2.2 Arbutus Biopharma (Tekmira)
        2.2.1 Arbutus Biopharma (Tekmira) Details
        2.2.2 Arbutus Biopharma (Tekmira) Major Business
        2.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions
        2.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.2.5 Arbutus Biopharma (Tekmira) Recent Developments and Future Plans
    2.3 Arrowhead
        2.3.1 Arrowhead Details
        2.3.2 Arrowhead Major Business
        2.3.3 Arrowhead RNAi for Therapeutic Product and Solutions
        2.3.4 Arrowhead RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.3.5 Arrowhead Recent Developments and Future Plans
    2.4 Dicerna Pharmaceuticals
        2.4.1 Dicerna Pharmaceuticals Details
        2.4.2 Dicerna Pharmaceuticals Major Business
        2.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions
        2.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.4.5 Dicerna Pharmaceuticals Recent Developments and Future Plans
    2.5 Mirna Therapeutics
        2.5.1 Mirna Therapeutics Details
        2.5.2 Mirna Therapeutics Major Business
        2.5.3 Mirna Therapeutics RNAi for Therapeutic Product and Solutions
        2.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.5.5 Mirna Therapeutics Recent Developments and Future Plans
    2.6 Quark Pharmaceuticals
        2.6.1 Quark Pharmaceuticals Details
        2.6.2 Quark Pharmaceuticals Major Business
        2.6.3 Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions
        2.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.6.5 Quark Pharmaceuticals Recent Developments and Future Plans
    2.7 RXi Pharmaceuticals
        2.7.1 RXi Pharmaceuticals Details
        2.7.2 RXi Pharmaceuticals Major Business
        2.7.3 RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions
        2.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.7.5 RXi Pharmaceuticals Recent Developments and Future Plans
    2.8 Silence Therapeutics
        2.8.1 Silence Therapeutics Details
        2.8.2 Silence Therapeutics Major Business
        2.8.3 Silence Therapeutics RNAi for Therapeutic Product and Solutions
        2.8.4 Silence Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.8.5 Silence Therapeutics Recent Developments and Future Plans
    2.9 Benitec Biopharma
        2.9.1 Benitec Biopharma Details
        2.9.2 Benitec Biopharma Major Business
        2.9.3 Benitec Biopharma RNAi for Therapeutic Product and Solutions
        2.9.4 Benitec Biopharma RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.9.5 Benitec Biopharma Recent Developments and Future Plans
    2.10 miRagen Therapeutics 
        2.10.1 miRagen Therapeutics Details
        2.10.2 miRagen Therapeutics Major Business
        2.10.3 miRagen Therapeutics RNAi for Therapeutic Product and Solutions
        2.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.10.5 miRagen Therapeutics Recent Developments and Future Plans
    2.11 Sylentis
        2.11.1 Sylentis Details
        2.11.2 Sylentis Major Business
        2.11.3 Sylentis RNAi for Therapeutic Product and Solutions
        2.11.4 Sylentis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.11.5 Sylentis Recent Developments and Future Plans
    2.12 Gradalis
        2.12.1 Gradalis Details
        2.12.2 Gradalis Major Business
        2.12.3 Gradalis RNAi for Therapeutic Product and Solutions
        2.12.4 Gradalis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.12.5 Gradalis Recent Developments and Future Plans
    2.13 Sirnaomics
        2.13.1 Sirnaomics Details
        2.13.2 Sirnaomics Major Business
        2.13.3 Sirnaomics RNAi for Therapeutic Product and Solutions
        2.13.4 Sirnaomics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.13.5 Sirnaomics Recent Developments and Future Plans
    2.14 Silenseed
        2.14.1 Silenseed Details
        2.14.2 Silenseed Major Business
        2.14.3 Silenseed RNAi for Therapeutic Product and Solutions
        2.14.4 Silenseed RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
        2.14.5 Silenseed Recent Developments and Future Plans
3 Market Competition, by Players
    3.1 Global RNAi for Therapeutic Revenue and Share by Players (2019, 2020, 2021, and 2022)
    3.2 Market Concentration Rate
        3.2.1 Top 3 RNAi for Therapeutic Players Market Share in 2021
        3.2.2 Top 10 RNAi for Therapeutic Players Market Share in 2021
        3.2.3 Market Competition Trend
    3.3 RNAi for Therapeutic Players Head Office, Products and Services Provided
    3.4 RNAi for Therapeutic Mergers & Acquisitions
    3.5 RNAi for Therapeutic New Entrants and Expansion Plans
4 Market Size Segment by Type
    4.1 Global RNAi for Therapeutic Revenue and Market Share by Type (2017-2022)
    4.2 Global RNAi for Therapeutic Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
    5.1 Global RNAi for Therapeutic Revenue Market Share by Application (2017-2022)
    5.2 Global RNAi for Therapeutic Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
    6.1 North America RNAi for Therapeutic Revenue by Type (2017-2028)
    6.2 North America RNAi for Therapeutic Revenue by Application (2017-2028)
    6.3 North America RNAi for Therapeutic Market Size by Country
        6.3.1 North America RNAi for Therapeutic Revenue by Country (2017-2028)
        6.3.2 United States RNAi for Therapeutic Market Size and Forecast (2017-2028)
        6.3.3 Canada RNAi for Therapeutic Market Size and Forecast (2017-2028)
        6.3.4 Mexico RNAi for Therapeutic Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
    7.1 Europe RNAi for Therapeutic Revenue by Type (2017-2028)
    7.2 Europe RNAi for Therapeutic Revenue by Application (2017-2028)
    7.3 Europe RNAi for Therapeutic Market Size by Country
        7.3.1 Europe RNAi for Therapeutic Revenue by Country (2017-2028)
        7.3.2 Germany RNAi for Therapeutic Market Size and Forecast (2017-2028)
        7.3.3 France RNAi for Therapeutic Market Size and Forecast (2017-2028)
        7.3.4 United Kingdom RNAi for Therapeutic Market Size and Forecast (2017-2028)
        7.3.5 Russia RNAi for Therapeutic Market Size and Forecast (2017-2028)
        7.3.6 Italy RNAi for Therapeutic Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific RNAi for Therapeutic Revenue by Type (2017-2028)
    8.2 Asia-Pacific RNAi for Therapeutic Revenue by Application (2017-2028)
    8.3 Asia-Pacific RNAi for Therapeutic Market Size by Region
        8.3.1 Asia-Pacific RNAi for Therapeutic Revenue by Region (2017-2028)
        8.3.2 China RNAi for Therapeutic Market Size and Forecast (2017-2028)
        8.3.3 Japan RNAi for Therapeutic Market Size and Forecast (2017-2028)
        8.3.4 South Korea RNAi for Therapeutic Market Size and Forecast (2017-2028)
        8.3.5 India RNAi for Therapeutic Market Size and Forecast (2017-2028)
        8.3.6 Southeast Asia RNAi for Therapeutic Market Size and Forecast (2017-2028)
        8.3.7 Australia RNAi for Therapeutic Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
    9.1 South America RNAi for Therapeutic Revenue by Type (2017-2028)
    9.2 South America RNAi for Therapeutic Revenue by Application (2017-2028)
    9.3 South America RNAi for Therapeutic Market Size by Country
        9.3.1 South America RNAi for Therapeutic Revenue by Country (2017-2028)
        9.3.2 Brazil RNAi for Therapeutic Market Size and Forecast (2017-2028)
        9.3.3 Argentina RNAi for Therapeutic Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa RNAi for Therapeutic Revenue by Type (2017-2028)
    10.2 Middle East & Africa RNAi for Therapeutic Revenue by Application (2017-2028)
    10.3 Middle East & Africa RNAi for Therapeutic Market Size by Country
        10.3.1 Middle East & Africa RNAi for Therapeutic Revenue by Country (2017-2028)
        10.3.2 Turkey RNAi for Therapeutic Market Size and Forecast (2017-2028)
        10.3.3 Saudi Arabia RNAi for Therapeutic Market Size and Forecast (2017-2028)
        10.3.4 UAE RNAi for Therapeutic Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Global RNAi for Therapeutic Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?